- Sam Chawla, of Perceptive Advisors, to resign from VBI Board of Directors
- Tomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI's Board of Directors
Jeff Baxter further commented, "We would like to thank Ran for his brief, but dynamic, service to VBI and we are honored to welcome Tomer to our Board of Directors. Tomer's broad management experience will complement the existing expertise on our Board, and his appointment will continue to strengthen VBI's relationships with Israeli strategic investors."In addition to his role at The Pontifax Group, Mr. Kariv also serves as an active board member of many of the funds' portfolio companies. Mr. Kariv holds a B.A. in Economics from Harvard University, and a J.D. from Harvard Law School. About VBI Vaccines Inc. VBI Vaccines Inc. ("VBI") is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI's first marketed product is Sci-B-Vac™, a hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI's eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (CMV) and glioblastoma multiforme (GBM). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that enables vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
VBI ContactNicole Anderson, Communications ExecutivePhone: (617) 830-3031 x124Email: firstname.lastname@example.org VBI Investor Contact Nell Beattie, Chief Business OfficerPhone: (617) 830-3031 x128Email: IR@vbivaccines.com VBI Media Contact Matt Middleman, M.D.LifeSci Public RelationsPhone: (646) 627-8384Email: email@example.com